Opinion

Video

Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

Author(s):

A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.

Video Player is loading.
Current Time 0:00
Duration 4:45
Loaded: 0.00%
Stream Type LIVE
Remaining Time 4:45
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following question(s):

    • What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
    Related Content
    AJMC Managed Markets Network Logo
    CH LogoCenter for Biosimilars Logo